<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04072354</url>
  </required_header>
  <id_info>
    <org_study_id>SEP361-301</org_study_id>
    <secondary_id>2019-000470-36</secondary_id>
    <nct_id>NCT04072354</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Subjects With Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sunovion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A clinical trial to study the efficacy and safety of an investigational drug in acutely
      psychotic people with schizophrenia. Participants in the study will either receive the drug
      being studied or a placebo. This study is accepting male and female participants between 13
      years old -65 years old who have been diagnosed with schizophrenia. This study will be
      conducted in 50 locations worldwide. The study will last up to 9 weeks total time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, parallel-group, fixed-dosed study evaluating
      the efficacy and safety of two doses of SEP-363856 (50 and 75 mg/day) versus placebo over a
      6-week Treatment Period in acutely psychotic subjects with schizophrenia. This study is
      projected to randomize approximately 435 subjects (18-65 years) to 3 treatment groups
      (SEP-363856 50 mg/day, SEP-363856 75 mg/day, or placebo) in a 1:1:1 ratio. In addition, the
      study will randomize approximately 90 adolescent subjects (13-17 years) in a 1:1:1 ratio to
      the 3 treatment groups (with approximately 30 subjects per group) in a separate cohort.
      Treatment assignment will be stratified by country. Study drug will be taken once a day and
      may be taken with or without food.

      This study is designed to test the hypothesis that, treatment with SEP-363856 in adult
      subjects with schizophrenia will result in significantly greater reduction (i.e. improvement)
      in PANSS total score and CGI-S score at Week 6 from Baseline when compared to placebo. The
      overall Type I error is controlled for two hierarchical families of hypotheses. The first
      family includes hypotheses about the testing of change from Baseline in PANSS total score at
      Week 6 between each of the SEP-363856 dose levels vs. placebo. The second family of
      hypotheses are about the testing of change from Baseline in CGI-S score at Week 6 between
      each of the SEP-363856 dose levels vs. placebo.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 11, 2019</start_date>
  <completion_date type="Anticipated">September 3, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind, parallel-group, placebo controlled, fixed-dose multicenter study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Positive and negative syndrome scale (PANSS) total score at Endpoint (Week 6)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Clinical Global Impressions - Severity (CGI-S) score at Endpoint (Week 6)</measure>
    <time_frame>Baseline and Week 6</time_frame>
    <description>The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">525</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>SEP-363856 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEP-363856 50mg dosed once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SEP-363856 75mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SEP-363856 75mg dosed once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo dosed once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP-363856 50mg</intervention_name>
    <description>SEP-363856 50mg tablet dosed once daily</description>
    <arm_group_label>SEP-363856 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SEP-363856 75mg</intervention_name>
    <description>SEP-363856 75mg tablet dosed once daily</description>
    <arm_group_label>SEP-363856 75mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet dosed once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subject between 13 to 65 years of age (inclusive) at the time of
             consent.

          2. Subject or subjects parent/legal guardian [adolescents] must give written informed
             consent and privacy authorization prior to participate in the study; adolescents must
             also provide informed assent..

          3. Subject meets DSM-5 criteria for schizophrenia as established by clinical interview

          4. Subject must have a CGI-S score ≥ 4

          5. Subject must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 on 2 or more of
             the following PANSS items: delusions, conceptual disorganization, hallucinations, and
             unusual thought content

          6. Subject has an acute exacerbation of psychotic symptoms (persisting no longer than 2
             months prior to providing informed consent).

          7. Subject has marked deterioration of functioning in one or more areas.

          8. Subject is, in the opinion of the Investigator, generally healthy based on screening
             medical history, PE, neurological examination, vital signs, and clinical laboratory
             values.

        Exclusion Criteria:

          1. Subject has a DSM-5 diagnosis or presence of symptoms consistent with a DSM-5
             diagnosis other than schizophrenia. Exclusionary disorders include but are not limited
             to alcohol use disorder (within past 12 months), substance (other than nicotine or
             caffeine) use disorder within past 12 months, major depressive disorder, bipolar I or
             II disorder, schizoaffective disorder, obsessive compulsive disorder, and
             posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety
             are allowed so long as these symptoms are not the primary focus of treatment.

          2. Subject is at significant risk of harming self, others, or objects based on
             Investigator's judgment.

          3. Subject has any clinically significant unstable medical condition or any clinically
             significant chronic disease that in the opinion of the Investigator, would limit the
             subject's ability to complete and/or participate in the study:

          4. Female subject who is pregnant or lactating

          5. Subject has any clinically significant abnormal laboratory value(s) at Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>CNS Medical Director</last_name>
    <role>Study Chair</role>
    <affiliation>Sunovion Pharmaceuticals In.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CNS Medical Director</last_name>
    <phone>1-866-503-6351</phone>
    <email>ClinicalTrialDisclosure@sunovion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Woodland International Research Group, LLC</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jim Aukstuolis, MD</last_name>
      <phone>501-221-8681</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Synergy San Diego</name>
      <address>
        <city>Lemon Grove</city>
        <state>California</state>
        <zip>91945</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Bari, MD</last_name>
      <phone>619-303-6130</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Alliance for Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90807</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Zarate-Rowell, MD</last_name>
      <phone>562-548-8500</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Volk, MD</last_name>
      <phone>909-590-8409</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Catalina Research Institute</name>
      <address>
        <city>Montclair</city>
        <state>California</state>
        <zip>91763</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Volk, MD</last_name>
      <phone>909-590-8409</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>NRC Research Institute</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Chueh, MD</last_name>
      <phone>714-289-1100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>California Neuropsychopharmacology Clinical Research Institute (CNRI-LA, LLC)</name>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <zip>90660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raymond Manning, MD</last_name>
      <phone>562-928-8601</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Centers of America</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Ventre, MD</last_name>
      <phone>954-990-7649</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Center for Medical Research</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30331</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Risenberg, MD</last_name>
      <phone_ext>404-881-5800</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CBH Health, LLC</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Litman, MD</last_name>
      <phone>301-251-4702</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Research of Southern Nevada, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Childress, MD</last_name>
      <phone>702-838-0742</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Midwest Clinical Research Center</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Otto Dueno, MD</last_name>
      <phone>937-424-1052</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Community Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78754</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brown, MD</last_name>
      <phone>512-323-2622</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Psychiatric Hospital - Pazardzhik AD-Department of Active Treatment of Men Department for Active Treatment of Woman Department of Active Treatment of Mean and Woman</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dora Atanasova, MD</last_name>
      <phone>+35934448812</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT-Dr. Georgi Stranski EAD-First Psychiatric clinic</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maya Stoimenova-Popova, MD</last_name>
      <phone>+359888227165</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mental Health Center-Sofia EOOD - Unit for Active Treatment of Persons with serious Mental Disorders</name>
      <address>
        <city>Sofia</city>
        <zip>1202</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emil Grashnov, MD</last_name>
      <phone>+359887508204</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Alexandrovska EAD, First Department of Psychiatry at Clinic of Psychiatry</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgi Onchev, MD</last_name>
      <phone>+359898474519</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMHAT Alexandrovska EAD, Second Department of Pshychiatry at Clinic of Psychiatry</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vihra Milanova, MD</last_name>
      <phone>+359888941451</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mental Health Center-Veliko Tarnovo EOOD-Deparmtentsof psychiatry for active treatment of persons with acute psychotic disorders</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ognan Nikitov, MD</last_name>
      <phone>+35962622625</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mental Health Center - Vratsa EOOD-Department of General Psychiatry</name>
      <address>
        <city>Vratsa</city>
        <zip>3000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadya Ivanova, MD</last_name>
      <phone>+359887422440</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetrary Institution of Healthcare Regional Clinical Specialized Psychiatric Hospital #1</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olga Golubchikova</last_name>
      <phone>+79193428436</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Republic Karelia &quot;Republican Psyhiatric Hospital&quot;</name>
      <address>
        <city>Karelia</city>
        <zip>186131</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Burkin, MD</last_name>
      <phone>+7921227235</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>SBIH of Moscow &quot;Psychiatric Clinical Hospital #4 n.a. P.B. Gannushkin&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Reznik, Professor</last_name>
      <phone>+74952635867</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare of nizhniy Novgorod region &quot;Clinical Psychiatric Hosptial #1 of Nizhniy Novgorod</name>
      <address>
        <city>Nizniy Novgorod</city>
        <zip>603155</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lala Kasimova, MD</last_name>
      <phone>+79030532505</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI 'NMRC of Psychiatry and Neurology named after V.M. Bekhterev MoH RF, department 12</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>192019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuriy Popov, MD</last_name>
      <phone>+79219335391</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Budgetary Institution of Healthcare &quot;Samara Regional Clinical Psychiatric Hospital&quot;</name>
      <address>
        <city>Samara</city>
        <zip>443016</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Sheyfer, MD</last_name>
      <phone>+78462074030</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>State Institution of Healthcare Saratov City Clninical Hospital #2, named after V.I. Razumovskiy psychiatric deparmtents</name>
      <address>
        <city>Saratov</city>
        <zip>410028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oksana A. Olevskaya</last_name>
      <phone>+78452392844</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>FSBI &quot;NMRC of Psychiatry and Neurology named after V.M. Bekhterev&quot; MoH RF, department 12</name>
      <address>
        <city>St. petersburg</city>
        <zip>092019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhail Popov, MD</last_name>
      <phone>+79214177511</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center &quot;Dr. Dragisa Misovic-Dedinje&quot; Clinic of Psychiatry</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Diligenski, PhD</last_name>
      <phone>+381113679200</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Mental Health</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cedo Miljevic, MD</last_name>
      <phone>+381628759575</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Special Hospital for Psychiartric Diseases Gornja Toponica, Stevana, Sindjelica 39</name>
      <address>
        <city>Gornja Toponica</city>
        <zip>18202</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milan Stanojkovic, MD</last_name>
      <phone>+831648596221</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Special Neuropsychiatric Hospital Kovin</name>
      <address>
        <city>Kovin</city>
        <zip>26220</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jovanka Petrovic, MD</last_name>
      <phone>+38163529054</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Center Kragujevac, Clinic of Psychiatry</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Vojvodina, Clinic of Psychiatry</name>
      <address>
        <city>Novi Sad</city>
        <zip>21000</zip>
        <country>Serbia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>15, Medychna St</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mykhailo Vynnyk, MD</last_name>
      <phone>+380976287390</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>2-A Metalurgiv st</name>
      <address>
        <city>Kropyvnytskyi</city>
        <zip>25491</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yevgen Denysov, MD</last_name>
      <phone>+380505641035</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Vladyslav Demchenko</name>
      <address>
        <city>Kyiv</city>
        <zip>02192</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladyslav Demchenko, MD</last_name>
      <phone>+380674081203</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>103 Kyrylivska St</name>
      <address>
        <city>Kyiv</city>
        <zip>04080</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuliya Blazhevych, MD</last_name>
      <phone>+380503847048</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Communal Noncommercial Enterprise of Lviv Regional Council Lviv Regional Clinical Psychiatric Hospital, Department #25</name>
      <address>
        <city>Lviv</city>
        <zip>79021</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuriy Filts, MD</last_name>
      <phone>+380322954900</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>9 Academician Vorobiov St</name>
      <address>
        <city>Odesa</city>
        <zip>65006</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anatolii Voloschuk, MD</last_name>
      <phone>+380637356555</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>1, Tsentraina Square, Oleksandrivka village, Lyman Region, Odesa Region</name>
      <address>
        <city>Odesa</city>
        <zip>67513</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oleksandr Mykhaylyukovych, MD</last_name>
      <phone>+380677550464</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>1 Medychna St</name>
      <address>
        <city>Poltava</city>
        <zip>36013</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrii Skyrpnikov, MD</last_name>
      <phone>+38502523300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Comm. Institution O.I. Yushchenko Vinnytsia Reg. Psychoneurologoical Hospital</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sofiia Rymsha, MD</last_name>
      <phone>+380679360338</phone>
    </contact>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute psychosis</keyword>
  <keyword>schizophrenia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study may be made available upon request via the Clinical Study Data Request site</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available upon request within 12 months of posting the study results on ct.gov.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

